Recent studies have demonstrated that DDX5 supports small-cell lung cancer progression by maintaining respiratory chain function, whereas Supinoxin induces metabolic collapse through the inhibition of the DDX5-ROS axis, suggesting mitochondrial dysfunction as a novel therapeutic target in efforts to overcome chemoresistance [2]. The gene discussed is DDX5; the disease is small cell lung carcinoma.